S-Tenatoprazole

Drug Profile

S-Tenatoprazole

Alternative Names: Benatoprazole; S-Tenatoprazole-Na; sTU-199; STU-Na; TU-199

Latest Information Update: 02 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Mitsubishi Pharma Corporation
  • Developer Abbott Japan; Mitsubishi Pharma Corporation; Negma SAS; Steba Laboratories
  • Class Antiulcers; Gastric antisecretories; Imidazoles; Pyridines; Small molecules
  • Mechanism of Action Proton pump inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Gastro-oesophageal reflux
  • Discontinued Peptic ulcer; Zollinger-Ellison syndrome

Most Recent Events

  • 31 Jul 2017 Phase-I clinical trials in Gastro-oesophageal reflux in Europe (PO) (Mitsubishi Tanabe Pharma Corporation pipeline, July 2017)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Gastro-oesophageal-reflux in European Union (PO)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Gastro-oesophageal-reflux(In volunteers) in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top